Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. The Company's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2-agonist, and fluticasone furoate, an inhaled corticosteroid, delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium, a long-acting muscarinic antagonist, and vilanterol (VI), a long-acting beta2-agonist for the treatment of chronic obstructive pulmonary diseases.

Type
Public
HQ
Brisbane, US
Founded
1996
Size (employees)
12 (est)
Website
inva.com
Innoviva was founded in 1996 and is headquartered in Brisbane, US
Report incorrect company information

Innoviva Office Locations

Innoviva has an office in Brisbane
Brisbane, US (HQ)
500 2000 Sierra Point Pkwy
Show all (1)
Report incorrect company information

Innoviva Financials and Metrics

Innoviva Financials

Innoviva's revenue was reported to be $133.57 m in FY, 2016 which is a 147.6% increase from the previous period.
USD

Revenue (Q2, 2017)

58.6 m

Net income (Q2, 2017)

35.1 m

EBIT (Q2, 2017)

47.8 m

Market capitalization (31-Oct-2017)

1.3 b

Closing share price (31-Oct-2017)

12

Cash (30-Jun-2017)

127.6 m
Innoviva's current market capitalization is $1.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.8 m8.4 m53.9 m133.6 m

Revenue growth, %

77%540%148%

General and administrative expense

23.2 m

R&D expense

1.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

165 k934 k999 k6.9 m10.7 m13.6 m24.2 m32.5 m33.3 m40.5 m58.6 m

Cost of goods sold

188 k

Gross profit

(23 k)

Gross profit Margin, %

(14%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

143.5 m96.8 m159.2 m118 m

Inventories

10.4 m814 k766 k

Current Assets

483.2 m252.2 m214.3 m198 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

171.9 m125.3 m208.1 m119.6 m141.2 m149.6 m78.7 m151.8 m112.9 m93.2 m159.8 m127.6 m

Accounts Receivable

450 k

Inventories

9 m11 m

Current Assets

522.3 m389.2 m353.2 m273.5 m262.4 m244 m223.8 m196.7 m190.4 m186.1 m214.4 m198.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(170.7 m)(168.5 m)(18.8 m)59.5 m

Depreciation and Amortization

8.2 m12.2 m13.9 m14 m

Inventories

(3.1 m)(1.9 m)

Accounts Payable

1.6 m(7.7 m)818 k(690 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(47 m)(67.7 m)(63.6 m)(21.3 m)(10.7 m)(18.5 m)(23.1 m)4.4 m19 m34.1 m16.8 m52 m

Depreciation and Amortization

7 m10.4 m3.5 m7 m10.5 m3.5 m7 m

Inventories

Accounts Payable

1.8 m573 k1 m462 k154 k(242 k)(681 k)(290 k)2.2 m149 k
USDY, 2017

Revenue/Employee

4.2 m

Financial Leverage

-1.3 x
Show all financial metrics

Innoviva Operating Metrics

FY, 2016

Patents Issued

33
Show all operating metrics
Report incorrect company information